Swil-NewsTUE · NOV 17 · 2026 · ISSUE № 2026.11.17

Cross-topic event

NEJM publishes Phase 3 retatrutide obesity results, with 25% weight loss at the top dose over 80 weeks (Metabolism)

Oct 3, 20262 reports
← All events